JP2016511751A5 - - Google Patents

Download PDF

Info

Publication number
JP2016511751A5
JP2016511751A5 JP2015555353A JP2015555353A JP2016511751A5 JP 2016511751 A5 JP2016511751 A5 JP 2016511751A5 JP 2015555353 A JP2015555353 A JP 2015555353A JP 2015555353 A JP2015555353 A JP 2015555353A JP 2016511751 A5 JP2016511751 A5 JP 2016511751A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
follistatin
protein
seq
recombinant follistatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015555353A
Other languages
English (en)
Japanese (ja)
Other versions
JP6475639B2 (ja
JP2016511751A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/012996 external-priority patent/WO2014116981A1/en
Publication of JP2016511751A publication Critical patent/JP2016511751A/ja
Publication of JP2016511751A5 publication Critical patent/JP2016511751A5/ja
Application granted granted Critical
Publication of JP6475639B2 publication Critical patent/JP6475639B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015555353A 2013-01-25 2014-01-24 デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン Expired - Fee Related JP6475639B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361756996P 2013-01-25 2013-01-25
US61/756,996 2013-01-25
US201361915733P 2013-12-13 2013-12-13
US61/915,733 2013-12-13
PCT/US2014/012996 WO2014116981A1 (en) 2013-01-25 2014-01-24 Follistatin in treating duchenne muscular dystrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018203613A Division JP2019059730A (ja) 2013-01-25 2018-10-30 デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン

Publications (3)

Publication Number Publication Date
JP2016511751A JP2016511751A (ja) 2016-04-21
JP2016511751A5 true JP2016511751A5 (OSRAM) 2017-02-23
JP6475639B2 JP6475639B2 (ja) 2019-02-27

Family

ID=50159515

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015555353A Expired - Fee Related JP6475639B2 (ja) 2013-01-25 2014-01-24 デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン
JP2018203613A Pending JP2019059730A (ja) 2013-01-25 2018-10-30 デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018203613A Pending JP2019059730A (ja) 2013-01-25 2018-10-30 デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン

Country Status (12)

Country Link
US (2) US9957309B2 (OSRAM)
EP (1) EP2948161B1 (OSRAM)
JP (2) JP6475639B2 (OSRAM)
KR (1) KR102253597B1 (OSRAM)
CN (1) CN104902915B (OSRAM)
AU (2) AU2014209178B2 (OSRAM)
CA (1) CA2898121A1 (OSRAM)
EA (1) EA201590719A1 (OSRAM)
ES (1) ES2715710T3 (OSRAM)
IL (1) IL240024B (OSRAM)
MX (1) MX362105B (OSRAM)
WO (1) WO2014116981A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
TWI432449B (zh) 2007-02-02 2014-04-01 Acceleron Pharma Inc 衍生自ActRIIB的變體與其用途
KR20220002710A (ko) 2008-06-26 2022-01-06 악셀레론 파마 인코포레이티드 액티빈-actriia 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
AU2014209178B2 (en) * 2013-01-25 2018-11-08 Takeda Pharmaceutical Company Limited Follistatin in treating Duchenne muscular dystrophy
WO2014152832A1 (en) 2013-03-14 2014-09-25 Immusoft Corporation Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
KR102305109B1 (ko) * 2014-06-04 2021-09-27 악셀레론 파마 인코포레이티드 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
CN107636154A (zh) * 2015-03-26 2018-01-26 阿塞勒隆制药公司 促滤泡素抑制素相关的融合蛋白及其用途
CN116196389A (zh) * 2016-01-06 2023-06-02 康德生物医疗有限公司 用于预防和治疗杜氏肌肉萎缩症的方法和组合物
EP3423479A2 (en) * 2016-03-04 2019-01-09 Shire Human Genetic Therapies, Inc. Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy
JP2020519291A (ja) * 2017-05-12 2020-07-02 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 組み換えフォリスタチン−fc融合タンパク質およびデュシェンヌ型筋ジストロフィーの治療における使用
KR101822633B1 (ko) * 2017-08-22 2018-01-26 (주)진셀팜 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도
WO2019046903A1 (en) * 2017-09-08 2019-03-14 Baker Heart and Diabetes Institute THERAPEUTIC METHOD FOR INCREASING MUSCLE MASS IN A SUBJECT
WO2019178613A1 (en) * 2018-03-16 2019-09-19 Immusoft Corporation B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength
WO2019191204A1 (en) * 2018-03-28 2019-10-03 Acceleron Pharma Inc. Follistatin polypeptides for the treatment of muscle contracture
CA3094859A1 (en) * 2020-10-01 2022-04-01 Entos Pharmaceuticals Inc. Proteolipid vesicles formulated with fusion associated small transmembrane proteins
KR102361657B1 (ko) 2021-04-26 2022-02-14 주식회사 케이에스비튜젠 14-디옥시-11,12-디디히드로안드로그라폴라이드 석시네이트를 유효성분으로 함유하는 듀센형 근이영양증을 포함한 유전성 근육질환의 예방 또는 치료용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
CA2476654A1 (en) 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
US7355018B2 (en) * 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
WO2008030367A2 (en) * 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
EP2318028B1 (en) * 2008-06-26 2020-02-19 Acceleron Pharma Inc. Antagonists of soluble activin-actriia and uses for increasing red blood cell levels
KR20220002710A (ko) * 2008-06-26 2022-01-06 악셀레론 파마 인코포레이티드 액티빈-actriia 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
BR112012005225B8 (pt) * 2009-09-09 2023-01-10 Acceleron Pharma Inc Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
US9023890B2 (en) * 2009-12-02 2015-05-05 The Charlotte-Mecklenburg Hospital Authority Nitrate esters and their use for the treatment of muscle and muscle related diseases
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
SA113340642B1 (ar) 2012-06-15 2015-09-15 فايزر إنك أجسام مضادة معارضة محسنة ضد gdf-8 واستخداماتها
RS65556B1 (sr) 2012-09-13 2024-06-28 Bristol Myers Squibb Co Proteini domena skele na bazi fibronektina koji vezuju miostatin
AU2014209178B2 (en) * 2013-01-25 2018-11-08 Takeda Pharmaceutical Company Limited Follistatin in treating Duchenne muscular dystrophy
WO2014187807A1 (en) 2013-05-21 2014-11-27 Arcarios B.V. Follistatin derivatives
KR102305109B1 (ko) 2014-06-04 2021-09-27 악셀레론 파마 인코포레이티드 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
US10842886B2 (en) 2014-10-10 2020-11-24 Research Institute At Nationwide Children's Hospital Guided injections for AAV gene transfer to muscle

Similar Documents

Publication Publication Date Title
JP2016511751A5 (OSRAM)
JP2025000642A5 (OSRAM)
JP2020040969A5 (OSRAM)
JP2015522576A5 (OSRAM)
JP2016538885A5 (OSRAM)
JP2012529296A5 (OSRAM)
JP2018522563A5 (OSRAM)
JP2010519931A5 (OSRAM)
JP2013512678A5 (OSRAM)
JP2016519569A5 (OSRAM)
JP2020023567A5 (OSRAM)
JP2016516016A5 (OSRAM)
CN108307642B (zh) 改造的白介素12及其在制备治疗肿瘤药物中的用途
MX383971B (es) Composición farmacéutica para la prevención y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteína de fusión en la cual el péptido que penetra el tejido y la preparación del factor de crecimiento endotelial antivascular se fusionan.
JP2011511090A5 (OSRAM)
US20240002462A1 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
JP2019509735A5 (OSRAM)
CN107847565B (zh) 用于肌肉减少症治疗的包括胰高血糖素样肽-1受体激动剂的药物组合物
JP2019524090A5 (OSRAM)
JP2022546402A (ja) ウイルス感染症を処置するための組成物及び方法
JP2014529399A5 (OSRAM)
JP2020519291A5 (OSRAM)
JPWO2020206098A5 (OSRAM)
CN113321736A (zh) 一种长效化白介素15融合蛋白及其制备方法和应用
JP7413629B2 (ja) Igf-1異型体を発現させるdnaコンストラクトを用いた神経病症の治療